Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2019

Finite-Lived Intangible Assets [Line Items]

Schedule of Intangible Assets and Goodwill [Table Text Block]

	As of December 31, 2019					As of December 31, 2018
(in millions)	Gross Carrying Amount		Accumulated Amortization/Write-offs			Gross Carrying Amount		Accumulated Amortization/Write-offs
Amortizable intangible assets
Technology-related	$	12,020	$	(5,706	)	$	10,197	$	(5,266	)
Patents	525		(408		)	520		(393		)
Other intangible assets	1,754		(1,081		)	1,666		(958		)
	$	14,299	$	(7,195	)	$	12,383	$	(6,617	)
Indefinite-lived intangible assets
Goodwill	$	20,076	$	(9,900	)	$	17,811	$	(9,900	)
In-process research and development (IPR&D)	662		—			486		—
Technology-related	120		—			120		—
	$	20,858	$	(9,900	)	$	18,417	$	(9,900	)

Schedule of Goodwill [Table Text Block]

The following represents our goodwill balance by global reportable segment and our separately reported Specialty Pharmaceuticals operating segment:

(in millions)	MedSurg			Rhythm and Neuro			Cardiovascular			Specialty Pharmaceuticals		Total
Balance as of December 31, 2017	$	2,877		$	417		$	3,704		$	—	$	6,998
Reportable segment revisions	(1,379		)	1,379			—			—		—
Foreign currency fluctuations and other changes	(3		)	(22		)	(3		)	—		(29		)
Goodwill acquired	568			150			224			—		942
Balance as of December 31, 2018	$	2,063		$	1,924		$	3,925		$	—	$	7,911
Foreign currency fluctuations and other changes	(1		)	—			58			9		66
Goodwill acquired	—			268			1,712			238		2,218
Goodwill divested	—			—			(19		)	—		(19		)
Balance as of December 31, 2019	$	2,061		$	2,192		$	5,676		$	247	$	10,176

Schedule of Expected Amortization Expense [Table Text Block]

Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio as of December 31, 2019 is as follows (in millions):

Fiscal Year
2020	$	787
2021	750
2022	722
2023	708
2024	672